company news

News

Company News Industry News Hot Science News

Leads Biolabs Announces Updated Results for LBL-007 to be Presented at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

NANJING, China, June 1, 2023--Nanjing Leads Biolabs Co.，Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the latest updated clinical data on the safety and efficacy of its anti-LAG-3 (lymphocyte activating gene-3) antibody LBL-007 and toripalimab combination therap

Leads Biolabs Announces First Subject Dosed In Phase Ⅰ/Ⅱ Clinical Trial To Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody In Advanced Solid Tumors Including Ovarian Cancer

NANJING, China, April 27, 2023--Nanjing Leads Biolabs Co.，Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the first participant has been successfully dosed in a Phase Ⅰ/Ⅱ, first in human, multicenter, open-labeled, dose escalation and expansion study of LBL-033, a

Wechat QR code

Headquarters and R&D Center：18 E. Jialingjiang Str., Bldg. 03 Fl. 7, Nanjing 210019, P.R.C.

Pilot and production：122 Huakang Rd., Bldg. 05, Jiangbei New Area, Nanjing 210031,P.R.C.

025-83378099 wlzb@leadsbiolabs.com